首页> 外文期刊>Acta Haematologica >Detectiion of JAK2 Exoa 12 Mutatriorns JAK2 V617F-Negative Pollycythemtia Vera Patriernts by Cloning Technique
【24h】

Detectiion of JAK2 Exoa 12 Mutatriorns JAK2 V617F-Negative Pollycythemtia Vera Patriernts by Cloning Technique

机译:克隆技术检测JAK2 Exoa 12突变体JAK2 V617F阴性复膜性维拉毒素

获取原文
获取原文并翻译 | 示例
       

摘要

Introduction: The identification of mutations of the JAK2 gene is a useful marker in the diagnosis of polycythemia vera (PV) patients. We studied the frequency of JAK2 mutations in a group of PV patients because data are still very limited regarding this subject in Polish patients. Methods: The JAK2 V617F mutation was examined using the amplification refractory mutation system (ARMS)-PCR method. Direct sequencing and a cloning technique were performed to determine alternations in exon 12 of the JAK2 gene. Results: A group of 90 consecutive patients with a suspected diagnosis of polycythemia vera were investigated. In 91% of the cases, the JAK2 V617F mutation was identified. The remaining JAK2 V617F-negative patients were subjected to examination for JAK2 exon 12 by direct PCR product sequencing and the cloning technique. The following mutations were identified: H538-K539delinsL, E543-D544de1 and N542-E543de1. These exon 12 mutants constituted 50% of PV JAK2 V617F-negative group and 4.4% (out of 90) of all PV patients (JAK2 V617F-positive and JAK2 V617F-negative). Conclusion: Our results demonstrate the prevalence of JAK2 mutations (V617F and in exon 12) in PV cases. Moreover, the data show that direct sequencing is not an adequate technique for exon 12 mutation identification; therefore, appropriate methodology should be considered for using this molecular marker in the process of diagnosis. (C) 2016 S. Karger AG, Basel
机译:简介:JAK2基因突变的鉴定是诊断真性红细胞增多症(PV)患者的有用标志物。我们研究了一组PV患者中JAK2突变的频率,因为波兰患者中有关该主题的数据仍然非常有限。方法:采用扩增难治性突变系统(ARMS)-PCR方法检测JAK2 V617F突变。进行直接测序和克隆技术以确定JAK2基因的外显子12中的替代。结果:对一组连续90例怀疑诊断为真性红细胞增多症的患者进行了调查。在91%的病例中,发现了JAK2 V617F突变。其余的JAK2 V617F阴性患者通过直接PCR产物测序和克隆技术接受了JAK2外显子12的检查。鉴定出以下突变:H538-K539delinsL,E543-D544de1和N542-E543de1。这些外显子12突变体占PV JAK2 V617F阴性组的50%,占所有PV患者(JAK2 V617F阳性和JAK2 V617F阴性)的4.4%(占90%)。结论:我们的结果证明了PV病例中JAK2突变的流行(V617F和第12外显子)。此外,数据显示直接测序不是外显子12突变鉴定的适当技术。因此,应考虑在诊断过程中使用这种分子标记物的适当方法。 (C)2016 S.Karger AG,巴塞尔

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号